pharmaphorum September 11, 2024
A clinical trial has backed the safety and efficacy of one of Novo Nordisk’s weight-loss medicines in children as young as six, showing a significant drop in body mass index (BMI).
The study used the company’s older GLP-1 agonist therapy Saxenda (liraglutide), which requires a daily injection, rather than its top-selling once-weekly obesity drug Wegovy (semaglutide), and focused on children aged six to 11 with an average BMI of 31, putting them in the obesity category.
There are no FDA-approved therapies for this age group, although, Wegovy has been cleared since 2022 for use in children and adolescents aged 12 and over, and Saxenda for the same age range since 2020. Novo Nordisk has filed for approval to extend the...
Today's Sponsors
Today's Sponsor